Optimeos Life Sciences, Inc. — Form D/A
Optimeos Life Sciences, Inc. of PRINCETON, NJ, a company, filed a Form D amendment with the SEC on 2024-11-26. The offering totals $5.0M, of which $2.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-11-26
- Form: D/A
- Accession: 0001819114-24-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.0M
- Amount sold: $2.9M
- Remaining: $2.1M
- Investors: 5
- Date of first sale: 2023-06-26
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-486138
Issuer
- Name: Optimeos Life Sciences, Inc.
- CIK: 0001819114
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 174 NASSAU STREET, SUITE 334, PRINCETON, NJ, 08542
- Phone: 609-658-9839
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Benjamin K Doranz | Director | Princeton, NJ |
| Shahram Hejazi, PhD | Director | Princeton, NJ |
| Shahram Hejazi, PhD | Executive Officer | Princeton, NJ |
| Jason Smith | Related Person | EXTON, PA |
| Shahram Hejazi | Related Person | Princeton, NJ |
| Jason K Smith, PhD | Director | Princeton, NJ |
| Robert K Prud'homme, PhD | Director | Princeton, NJ |
| Robert Prud'homme, PhD | Director | Princeton, NJ |
| Jason Smith, PhD | Director | Princeton, NJ |
| Robert K Prud'homme | Related Person | Princeton, NJ |
| Benjamin Doranz | Related Person | Princeton, NJ |
Other filings by this issuer (4)
More